Abstract
Highly active antiretroviral therapy (HAART) has transformed HIV-1 infection from an invariably fatal disease into a chronic infection requiring lifelong treatment. However, the challenges we still face are the urgent need to provide affordable sustainable therapy to the millions of infected individuals who live in resource-poor countries, and the limitations posed by serious drug toxicity and viral resistance associated with long-term therapy. Augmentation of HIV-specific immunity by therapeutic vaccination is a possible alternative to continuous HAART. In this review, progress in the development of therapeutic immunization strategies is discussed.
Get full access to this article
View all access options for this article.